BHCM
PBYI icon

Brevan Howard Capital Management’s Puma Biotechnology PBYI Stock Holding History

Brevan Howard Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-49,875
Closed -$264K – 1327
2024
Q1 		$264K Buy
+49,875
New +$269K ﹤0.01% 699

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's PBYI Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 49,875 shares — an estimated $264K sold.

Brevan Howard Capital Management first reported a position in PBYI in Q1 2024 and held it in 1 quarter. The position peaked at $264K in Q1 2024. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 49,875 Puma Biotechnology shares in Q2 2024, an estimated $264K.
  • Brevan Howard Capital Management first reported a position in Puma Biotechnology in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Puma Biotechnology position peaked at $264K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.